Hemodialysis.com

Hemodialysis.com Author Interview :Joshua Barzilay MD

Albuminuria and Rapid Loss of GFR and Risk of New Hip and Pelvic Fractures

Joshua I. Barzilay, Peggy Gao, Catherine M. Clase, Andrew Mente, Johannes F.E. Mann, Peter Sleight, Salim Yusuf, and Koon K. Teo on behalf of the OnTARGET/TRANSCEND Investigators
Albuminuria and Rapid Loss of GFR and Risk of New Hip and Pelvic Fractures
CJASN CJN.06640712; published ahead of print November 26, 2012, doi:10.2215/CJN.06640712

Hemodialysis.com Authors' Interview: Efstathios Mitsopoulos

Impact of Long-Term Cinacalcet, Ibandronate or Teriparatide Therapy on Bone Mineral Density of Hemodialysis Patients: A Pilot Study.

Mitsopoulos E, Ginikopoulou E, Economidou D, Zanos S, Pateinakis P, Minasidis E, Memmos D, Thodis E, Vargemezis V, Tsakiris D:
Am J Nephrol 2012;36:238-244 (DOI: 10.1159/000341864)

Hemodialysis.com Authors' Interview:

Association of Pre-Kidney Transplant Markers of Mineral and Bone Disorder with Post-Transplant Outcomes

Miklos Z. Molnar, Csaba P. Kovesdy, Istvan Mucsi, Isidro B. Salusky, and Kamyar Kalantar-Zadeh
Outcomes CJASN CJN.01910212; published ahead of print September 6, 2012, doi:10.2215/CJN.01910212

Author Interview: Debbie Benner

FOCUSED CLINICAL CAMPAIGN IMPROVES MINERAL AND BONE DISORDER OUTCOMES. 

Benner, D., Nissenson, A. R. and Van Wyck, D. (2011), FOCUSED CLINICAL CAMPAIGN IMPROVES MINERAL AND BONE DISORDER OUTCOMES. Journal of Renal Care. doi: 10.1111/j.1755-6686.2011.00233.x

Author Interview: Christine Swafford, MS, RD, CSR, LD
Improving Mineral Bone Disease in Peritoneal Dialysis

Anuual Dialysis Conference March 2012 Poster

Author Interview: David M. Spiegel, MD, FACP

A Computerized Treatment Algorithm Trial to Optimize Mineral Metabolism in ESRD

David M. Spiegel, Lesley McPhatter, Ann Allison, Joanne C. Drumheller, and Robert Lockridge

CJASN CJN.08170811; published ahead of print February 2012 doi:10.2215/CJN.08170811

Author Interview: Bojan Kovacevic MD

Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism.

KBC Zvezdara University Clinical Centre, Clinic for Surgery "Nikola Spasic", D. Tucovica 161, 11000, Belgrade, Serbia,
Langenbecks Arch Surg. 2012 Jan 13. [Epub ahead of print]

Author Interview: Dr. Robert Perkins, MD

Bisphosphonate Therapy, Death, and Cardiovascular Events Among Female Patients With CKD: A Retrospective Cohort Study

James E. Hartle, Xiaoqin Tang, H. Lester Kirchner, Ion D. Bucaloiu, Jennifer A. Sartorius,
Zhanna V. Pogrebnaya, Gwendolyn A. Akers, Guillermo E. Carnero, Robert M. Perkins 
Nephrology Department, Geisinger Medical Center, Danville, PA

Publication:
Author Interview: Prof. Armando Luis Negri, MD, FACP

Evaluation of bone microarchitecture by high-resolution peripheral quantitativecomputed tomography (HR-pQCT) in hemodialysis patients.

Negri AL, Del Valle EE, Zanchetta MB, Nobaru M, Silveira F, 
Puddu M, Barone R, Bogado CE, Zanchetta JR.
Instituto de Investigaciones Metabólicas, Universidad del Salvador, Libertad 836 1 piso, Buenos Aires, 1012, Argentina
Osteoporos Int. 2012 Jan 11. [Epub ahead of print]

Miklos Z. Molnar, MD, PhD, and Kamyar Kalantar-Zadeh, MD, MPH, PhD
Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease

Lilia R. Lukowsky, Miklos Z. Molnar, Joshua J. Zaritsky, John J. Sim, Istvan Mucsi,Csaba P. Kovesdy, and Kamyar Kalantar-Zadeh
Dial. Transplant. first published online December 29, 2011 doi:10.1093/ndt/gfr747

Author Interview: T. Christopher Bond, Ph.D.

Effects of Switching from Intravenous Paricalcitol to Doxercalciferol on Dialysis Patient Bone and Mineral Outcomes

T. Christopher Bond, PhD, Steven M. Wilson, PhD, Mahesh Krishnan, MD, FASN, Tracy Jack Mayne, PhD.
DaVita Clinical Research, Minneapolis, MN.
ASN 2011 Abstract: [FR-PO1266]

Author Interview: Dr. Kuo-Cheng Lu, MD

Decreased blood lead levels after calcitriol treatment in hemodialysis patients with secondary hyperparathyroidism.
Lu KC, Wu CC, Ma WY, Chen CC, Wu HC, Chu P.
Bone. 2011 Oct 1. [Epub ahead of print]
Division of Nepheology, Department of Medicine, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan; Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

Author Interview: Dr. Peter Stenvinkel

Circulating Follistatin in Patients with Chronic Kidney Disease: Implications for Muscle Strength, Bone Mineral Density, Inflammation, and Survival

Clin J Am Soc Nephrol. 2011 May;6(5):1001-8.Miyamoto T, Carrero JJ, Rashid Qureshi A, Anderstam B, Heimbürger O, Bárány P, Lindholm B, Stenvinkel P.

Renal osteodystrophy in the first decade of the new millennium-analysis of 630 bone biopsies in black and white patients.

J Bone Miner Res. 2010 Dec 2.

Malluche HH, Mawad HW, Monier-Faugere MC.
Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington, KY, USA.

Do Differences in Dialysis Prescription Impact on KDOQI Bone Mineral Targets? The Pan Thames Renal Audit.

Blood Purif. 2010 Aug 12;30(2):111-117.

Davenport A, Gardner C, et al
UCL Center for Nephrology, Royal Free Campus, University College London Medical School, London, UK

KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of mineral and bone disorders in chronic kidney disease.

Pol Arch Med Wewn. 2010 Jul;120(7-8):300-6.
Matuszkiewicz-Rowinska J

Endogenous estrogen may prevent bone loss in postmenopausal hemodialysis patients throughout life.

Osteoporos Int. 2010 Jul 22.
Sugiya N, et al

Reversible bone pain and symmetric bone scan uptake in a dialysis patient treated with cinacalcet: a case report.
J Med Case Reports. 2010 Jun 24;4(1):191.
Lenz O, et al

Vertebral fractures in dialysis: Endocrinological disruption of the bone-kidney axis.
J Endocrinol Invest. 2010 May;33(5):347-352.
Fusaro M,